Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A quick and simplified method (QuickRibo-mRNA) for isolation of ribosome protected mRNA fragments for translatome identification

Award Number: R43GM142408
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/15/2021
PERIOD OF PERFORMANCE END DATE: 12/14/2022

Group Awards By:

View Award Description

A quick and simplified method (QuickRibo-mRNA) for isolation of ribosome protected mRNA fragments for translatome identification - The goal of this proposal is to establish and validate a novel method for the isolation of ribosome protected mRNA footprints for translatome identification. Translatome or Ribosome profiling (RP), a deep sequencing technique of ribosome-protected mRNA footprints, is a powerful method that gives a “snapshot” of actively translating mRNA. Revolutionizing the capacity to capture every step of mRNA translation at sub-codon resolution, it potentially allows one to monitor the rate and location of mRNA translation in the cell and annotate the new protein coding sequences of genomes. RP, therefore, affords a vast opportunity to explore and model complex cellular processes in real time. This methodology has been mined extensively in numerous diseases including cancer, immunology and neurology. RP identified several new micro-peptides and protein from COVID mRNA, further expanding its potential as a novel target-identification method. In this context, RP has emerged as a potent method to identify mRNA frameshifting and novel ORFs, and providing valuable insights for understanding functional elements of the genome, disease pathogenesis and evaluation of impact treatment in the case of mRNA therapeutics and cancer therapy in a gene and the tissues specific manner. However, RP applications are stunted and limited to specialized labs because it requires expertise, specialized instruments and time-consuming - taking up to ~5 days on an average. In turn, this affects the cost, quality of the final data and thereby obscuring the mRNA translational landscape. Given the power and potential for widespread use, there is an urgent and unmet need for alternative/improved RP technology similar to RNA purification methods which are less time consuming, free of artifacts and inexpensive. In Phase-I application, we proposed two specific aims to refine the QuickRibo-mRNA method, validate and compare it with current RP methods to establish its efficacy. In aim-1 we will establish and validate the QuickRibo-mRNA methodology in various conditions and cell types in obtaining uniform ribosome protected mRNA fragments with improved percent read mapping to coding sequences. In aim-2 we will compare the efficacy of QuickRibo-mRNA with known ribosome profiling technologies. We believe that phase-I proposal will provide a benchmark for phase II, which can streamline the QuickRibo-mRNA method for performing ribosome profiling with high reproducibility and efficiency. In the end RP will be done proficiently in the simplest way with less time, instrumentation and expertise to identify gene “expression with reading frames and translation efficiency” before making any conclusions entirely based on RNA-gene “expression profile”.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2021	RIBO-THERAPEUTICS LLC	6076 CORTE DEL CEDRO	CARLSBAD	CA	92011	SAN DIEGO	USA	Biomedical Research and Research Training	000	1	8/30/2023	NEW	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $301,818 )
2021	2021	RIBO-THERAPEUTICS LLC	6076 CORTE DEL CEDRO	CARLSBAD	CA	92011	SAN DIEGO	USA	Biomedical Research and Research Training	000	1	9/14/2021	NEW	$301,818
														Subtotal = $301,818

Grand Total All Awards = $301,818

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A quick and simplified method (QuickRibo-mRNA) for isolation of ribosome protected mRNA fragments for translatome identification

Award Number: R43GM142408

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/15/2021

PERIOD OF PERFORMANCE END DATE: 12/14/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer